In a surprising turn of events, the FDA's top drug regulator, Richard Pazdur, is considering stepping down from his influential position. But the plot thickens—he might not be leaving after all! Pazdur has submitted retirement paperwork, but sources hint that he could change his mind, leaving the FDA's future leadership in question.
This development comes just weeks after Pazdur's appointment as the director of the Center for Drug Evaluation and Research (CDER) at the FDA, a role he assumed at the request of FDA Commissioner Marty Makary. The timing couldn't be more intriguing, as it adds a layer of uncertainty to an already tumultuous period for the agency.
But here's where it gets controversial: Was Pazdur's appointment as CDER director a short-lived experiment, or is there more to the story? The FDA has been navigating significant changes, and Pazdur's potential departure could signal a shift in the agency's direction.
Our reporter Lizzy Lawrence, who heads STAT's coverage of the FDA, has been closely following this story. Lizzy, a former medical devices reporter, is available on Signal at lizzylaw.53 for any further insights or questions you may have.
The FDA's leadership changes have been making headlines, and this latest twist is sure to spark discussion. What does Pazdur's potential retirement mean for the agency's future? Share your thoughts in the comments below, and let's explore the implications together.
